 Brookline Capital Management assumed coverage on shares of Moderna NASDAQ:MRNA in a research report sent to investors on Monday, Stock Target Advisor reports. The brokerage issued a buy rating and a 95.00 price target on the stock. MRNA has been the subject of several other research reports. Morgan Stanley increased their price target on shares ... 